A Comparative Review of the Options for Treatment of Erectile Dysfunction
- 1 January 2005
- journal article
- research article
- Published by Springer Science and Business Media LLC in Drugs
- Vol. 65 (12), 1621-1650
- https://doi.org/10.2165/00003495-200565120-00003
Abstract
The field of erectile dysfunction (ED) has been revolutionised over the last two decades. Several treatment options are available today, most of which are associated with high efficacy rates and favourable safety profiles. A MEDLINE search was undertaken in order to evaluate all currently available data on treatment modalities for ED. Phosphodiesterase type 5 (PDE5) inhibitors (sildenafil, tadalafil, vardenafil) are currently the first-choice of most physicians and patients for the treatment of ED. PDE5 inhibitors have differences in their pharmacological profiles, the most obvious being the long duration of action of tadalafil, but there are no data supporting superiority for any one of them in terms of efficacy or safety. Sublingual apomorphine has limited efficacy compared with the PDE5 inhibitors, and its use is limited to patients with mild ED. Treatment failures with oral drugs may be due to medication, clinician and patient issues. The physician needs to address all of these issues in order to identify true treatment failures. Patients who are truly unresponsive to oral drugs may be offered other treatment options. Intracavernous injections of alprostadil alone, or in combination with other vasoactive agents (papaverine and phentolamine), remain an excellent treatment option, with proven efficacy and safety over time. Topical pharmacotherapy is appealing in nature, but currently available formulations have limited efficacy. Vacuum constriction devices may be offered mainly to elderly patients with occasional intercourse attempts, as younger patients show limited preference because of the unnatural erection that is associated with this treatment modality. Penile prostheses are generally the last treatment option offered, because of invasiveness, cost and non-reversibility; however, they are associated with high satisfaction rates in properly selected patients. All treatment options are associated with particular strengths and weaknesses. A patient-centred approach based on patient needs and expectations is necessary for the management of ED. The clinician must educate the patient and provide a supportive environment for shared decision making. The management strategy must be supplemented by careful follow-up in order to identify changes in patient health and relationship/emotional status that may necessitate treatment optimisation.Keywords
This publication has 100 references indexed in Scilit:
- AMS Three–Piece Inflatable Implants for Erectile Dysfunction: A Long–Term Multi–Institutional Study in 200 Consecutive PatientsEuropean Urology, 2000
- SildenafilDrugs, 1999
- Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatment of patients with erectile dysfunction resistant to other intracavernosal agentsBJU International, 1998
- Comparison of intraurethral liposomal and intracavernosal prostaglandin-E1 in the management of erectile dysfunctionBJU International, 1998
- Intracavernosal drug‐induced erection therapy versus external vacuum devices in the treatment of erectile dysfunctionBJU International, 1997
- External vacuum therapy for erectile dysfunction: use and resultsWorld Journal of Urology, 1997
- Treatment of Men with Erectile Dysfunction with Transurethral AlprostadilThe New England Journal of Medicine, 1997
- Long‐term follow‐up of patients with erectile dysfunction commenced on self injection with intracavernosal papaverine with or without phentolamineBJU International, 1996
- Vacuum constriction devices in erectile dysfunction: acceptance and effectiveness in patients with impotence of organic or mixed aetiologyBJU International, 1994
- Successful non-invasive management of erectile impotence in diabetic menBMJ, 1988